For more information contact:
John L. Tonkinson, Ph.D., Chief Business Development Officer
Main: +1-760-804-3886 | Mobile: +1-860-977-4012
FOR IMMEDIATE RELEASE
November 7, 2018
Rapid Pathogen Screening, Inc. wins $10,000 Innovation Award at the Advanced Lateral Flow Course
CARLSBAD, Calif. – DCN Dx, a developer and manufacturer of rapid point-of-care diagnostic tests, and QIAGEN Lake Constance announced today that Rapid Pathogen Screening, Inc. (RPS) was the winner of the first $10,000 Innovation Award at the Advanced Lateral Flow Course. RPS was selected from 38 entrants that described advances in diagnostic technology.
RPS’s technology, called FebriDx, helps reduce unnecessary use of antibiotics in acute febrile respiratory infection (ARI). FebriDx is a rapid point-of-care test that can identify patients with clinically significant underlying infection and can aid in the differentiation of viral and bacterial ARI’s in 10 minutes and at a fraction of the cost of traditional laboratory tests. These results will aid in the reduced broad use of unnecessary antibiotics, which contribute to antibiotic resistance.
“We are extremely pleased that Rapid Pathogen Screening was awarded the First Innovation Award at the ALFC,” said Brendan O’Farrell, Ph.D., co-founder and president of DCN Dx. “The power of lateral flow technology is becoming increasingly apparent in diverse applications, and RPS’s innovation to apply it to help reduce the use of unnecessary antibiotics is truly a huge step forward,” said O’Farrell.
“The technology developed by Rapid Pathogen Screening truly fills a gap in rapid point-of-care diagnostics that doctors have been waiting for,” said Michael Doumanas, director of strategic alliances at QIAGEN Lake Constance. “The Innovation Award recognizes this achievement. We are convinced that we will see many future innovations applying lateral flow technology.”
Over the past 6 years, the Advanced Lateral Flow Course has developed into the premier scientific and industrial event for bringing together scientists, engineers, developers and manufacturers of point-of-care tests. This year’s event drew 200 people from around the world from academia, start-up companies, large companies and government agencies. The Innovation Award recognizes the best innovation in diagnostic technology over the past year and comes with a $10,000 cash prize.
The Advanced Lateral Flow Course and its Innovation Award are sponsored by DCN Dx and Qiagen Lake Constance.
Since its founding more than 12 years ago, DCN Dx has been committed to furthering the rapid diagnostic test market through the continued evolution of technologies and applications related to lateral flow assays. For more information about DCN Dx, visit dcndx.com.
QIAGEN Lake Constance GmbH, a subsidiary of QIAGEN N.V., develops and produces innovative optical measuring instruments and detection units for the fields of biotechnology, medical technology, diagnostics, veterinary, environment and industry. The easy to use original equipment manufacturer (OEM) products enable our customers to develop their final product, either a lateral flow technology or a nucleic acid-based / isothermal amplification assays device. The OEM product range includes the development and production of portable instruments for point-of-need testing. QIAGEN Lake Constance GmbH cooperates internationally with various institutes and research facilities with an additional focus on the system integration of microfluidic test formats.